The three largest U.S. drug distributors, facing their first trial over claims that they fueled the opioid crisis, said responsibility for ballooning painkiller sales lies with doctors, drugmakers and regulators.

Four drugmakers, including Johnson & Johnson and Teva Pharmaceutical Industries Ltd., will go to trial on April 19 over claims they helped fuel an opioid crisis that has resulted in nearly 500,000 overdose deaths in the United States.

Three major U.S. drug distributors requested the government to expand the Covid-19 vaccine supply chain network as the country strives to immunize its population against the novel coronavirus as quickly as possible.

McKesson Corp. said the company and two other major U.S. drug distributors could be expected to pay up to $21 billion under a new proposal by state attorneys general to resolve lawsuits alleging they helped fuel the U.S. opioid crisis.

Johnson & Johnson will contribute up to $1 billion more to a potential settlement of lawsuits alleging the New Brunswick, New Jersey-based drugmaker and other companies fueled the U.S. opioid epidemic, bringing J&J’s total payment to $5 billion.

A federal appeals court overturned a judge’s approval of a novel plan by lawyers representing cities and counties suing drug companies over the U.S. opioid crisis that would bring every community nationally into their settlement talks.

Twenty one states rejected an $18 billion settlement proposal from three major U.S. drug distributors to resolve lawsuits over their alleged role in the opioid crisis, although settlement discussions continue, according to two sources familiar with the matter.

Federal prosecutors are investigating six pharmaceutical companies for potential criminal charges in connection with shipping large quantities of opioid painkillers that contributed to a healthcare crisis, according to regulatory filings.

New York’s insurance regulator formally notified a group of opioid manufacturers and distributors that the NYDFS will launch a civil enforcement action against them for contributing towards a rise in health insurance premiums in the state, said two sources familiar with the matter.

Four large drug companies reached a last-minute $260 million legal settlement over their role in the U.S. opioid addiction epidemic, averting the first federal trial that was scheduled to start in Cleveland.